​

Guardant Health (GH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GH Stock Forecast

Guardant Health (GH) stock forecast, based on 30 Wall Street analysts, predicts a 12-month average price target of $97.00, with a high of $140.00 and a low of $70.00. This represents a -4.28% decline from the last price of $101.34.

- $30 $60 $90 $120 $150 High: $140 Avg: $97 Low: $70 Last Closed Price: $101.34

GH Stock Rating

Guardant Health stock's rating consensus is Buy, based on 30 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 29 Buy (96.67%), 0 Hold (0.00%), 1 Sell (3.33%), and 0 Strong Sell (0.00%).

Buy
Total 30 1 29 Strong Sell Sell Hold Buy Strong Buy

GH Price Target Upside V Benchmarks

TypeNameUpside
StockGuardant Health-4.28%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks6.89%

Price Target Trends

1M3M12M
# Anlaysts21416
Avg Price Target$135.00$92.71$88.75
Last Closing Price$101.34$101.34$101.34
Upside/Downside33.21%-8.52%-12.42%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25517-1-23
Nov, 25517--123
Oct, 25518--124
Sep, 255161-123
Aug, 256162--24
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 12, 2025BTIG$140.00$101.3438.15%38.15%
Dec 01, 2025Tejas SavantMorgan Stanley$130.00$105.2223.55%28.28%
Oct 30, 2025Dan LeonardUBS$110.00$95.2915.44%8.55%
Oct 30, 2025Mark MassaroBTIG$100.00$95.554.66%-1.32%
Oct 30, 2025Bradley BowersMizuho Securities$100.00$72.2738.37%-1.32%
Oct 30, 2025Kyle MiksonCanaccord Genuity$100.00$72.2738.37%-1.32%
Oct 30, 2025Barclays$85.00$72.2717.61%-16.12%
Oct 22, 2025Piper Sandler$90.00$67.5133.31%-11.19%
Oct 02, 2025Barclays$70.00$62.6511.73%-30.93%
Sep 26, 2025Kyle MiksonCanaccord Genuity$75.00$60.1824.63%-25.99%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 12, 2025BTIGBuyBuyhold
Dec 11, 2025CitigroupBuyBuyhold
Oct 30, 2025Cowen & Co.BuyBuyhold
Oct 30, 2025UBSBuyBuyhold
Oct 30, 2025CitigroupBuyBuyhold
Oct 30, 2025BTIGBuyBuyhold
Oct 30, 2025BarclaysOverweightOverweighthold
Oct 30, 2025Canaccord GenuityBuyBuyhold
Oct 22, 2025Piper SandlerOverweightOverweighthold
Oct 02, 2025BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.53$-3.80$-6.41$-4.28$-3.56----
Avg Forecast$-2.18$-4.26$-6.45$-3.58$-3.41$-2.90$-2.46$-2.32$-2.13
High Forecast$-2.10$-4.11$-6.26$-3.49$-3.32$-2.26$-1.18$-0.24$-2.04
Low Forecast$-2.23$-4.36$-6.80$-3.68$-3.50$-3.73$-2.99$-3.72$-2.29
Surprise %16.06%-10.80%-0.62%19.55%4.40%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$286.73M$373.65M$449.54M$563.95M$739.02M----
Avg Forecast$284.99M$364.29M$446.54M$558.07M$729.04M$846.27M$1.02B$1.23B$1.46B
High Forecast$289.97M$370.66M$464.85M$589.10M$729.24M$868.09M$1.02B$1.24B$1.54B
Low Forecast$277.20M$354.33M$435.97M$538.39M$728.83M$819.82M$1.02B$1.22B$1.41B
Surprise %0.61%2.57%0.67%1.05%1.37%----

Net Income Forecast

$-700M $-560M $-420M $-280M $-140M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-246.28M$-384.77M$-654.59M$-479.45M$-436.37M----
Avg Forecast$-221.25M$-372.37M$-508.71M$-479.45M$-382.22M$-364.59M$-312.67M$-168.64M$-238.87M
High Forecast$-177.00M$-297.90M$-406.97M$-383.56M$-372.11M$-252.82M$-132.14M$-27.21M$-227.92M
Low Forecast$-265.50M$-446.85M$-610.45M$-575.34M$-392.33M$-417.56M$-334.31M$-416.51M$-256.14M
Surprise %11.31%3.33%28.68%-14.17%----

GH Forecast FAQ

Is Guardant Health stock a buy?

Guardant Health stock has a consensus rating of Buy, based on 30 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 29 Buy, 0 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Guardant Health is a favorable investment for most analysts.

What is Guardant Health's price target?

Guardant Health's price target, set by 30 Wall Street analysts, averages $97 over the next 12 months. The price target range spans from $70 at the low end to $140 at the high end, suggesting a potential -4.28% change from the previous closing price of $101.34.

How does Guardant Health stock forecast compare to its benchmarks?

Guardant Health's stock forecast shows a -4.28% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (6.89%).

What is the breakdown of analyst ratings for Guardant Health over the past three months?

  • December 2025: 21.74% Strong Buy, 73.91% Buy, 0% Hold, 4.35% Sell, 0% Strong Sell.
  • November 2025: 21.74% Strong Buy, 73.91% Buy, 0% Hold, 0% Sell, 4.35% Strong Sell.
  • October 2025: 20.83% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 4.17% Strong Sell.

What is Guardant Health’s EPS forecast?

Guardant Health's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.9, marking a -18.54% decrease from the reported $-3.56 in 2024. Estimates for the following years are $-2.46 in 2026, $-2.32 in 2027, and $-2.13 in 2028.

What is Guardant Health’s revenue forecast?

Guardant Health's average annual revenue forecast for its fiscal year ending in December 2025 is $846.27M, reflecting a 14.51% increase from the reported $739.02M in 2024. The forecast for 2026 is $1.02B, followed by $1.23B for 2027, and $1.46B for 2028.

What is Guardant Health’s net income forecast?

Guardant Health's net income forecast for the fiscal year ending in December 2025 stands at $-365M, representing a -16.45% decrease from the reported $-436M in 2024. Projections indicate $-313M in 2026, $-169M in 2027, and $-239M in 2028.